Stay updated with breaking news from Cutaneous Lymphomas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company...
Skin cancer is the most common cancer in the world. HELLO! spoke to Dr. Peter Dziewulski to understand the disease in more detail, including signs, types and treatment options
MARSEILLE, France, October 05, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The partial clinical hold follows one fatal case of hemophagocytic lymphohistiocytosis (HLH), a rare
The retrospective study analyzed data on 149 patients with CTCL who were being managed at one of nine international academic medical centers in seven countries from March through October 2020.
Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients with myco